1. Secondary prevention and follow-up of patients with ACS and not-at-target LDL: An Italian real-world retro-prospective analysis by the INERTIA group
- Author
-
Maurizio Del Pinto, Francesco Amico, Natale Brunetti, Pasquale Caldarola, Stefano Carugo, Claudio Cavallini, Antonello D'Andrea, Francesco Fedele, Ciro Mauro, Patrizia Noussan, Leonardo Paloscia, Francesco Prati, Pierpaolo Tarzia, Maurizio Tespili, Lucia Barbieri, Pierangelo Basso, Andrea Buono, Alberto D'Alleva, Simona Giubilato, Mario Iannacone, Fabio Ferrante, Giuseppina Granata, Riccardo Ieva, Alfredo Madrid, Maria Teresa Mallus, and Ercole Tagliamonte
- Subjects
Acute coronary syndrome ,LDL cholesterol ,Follow-up ,Target ,Statin ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Background: In patients with recent ACS, the latest ESC/EAS guidelines for management of dyslipidaemia recommend intensification of LDL-C-lowering therapy. Objective: Report a real-world picture of lipid-lowering therapy prescribed and cholesterol targets achieved in post-ACS patients before and after a specific educational program. Methods: Retrospective data collection prior to the educational course and prospective data collection after the course of consecutive very high-risk patients with ACS admitted in 2020 in 13 Italian cardiology departments, and with a non-target LDL-C level at discharge. Results: Data from 336 patients were included, 229 in the retrospective phase and 107 in the post-course prospective phase. At discharge, statins were prescribed in 98.1% of patients, alone in 62.3% of patients (65% of which at high doses) and in combination with ezetimibe in 35.8% of cases (52% at high doses). A significant reduction was obtained in total and LDL cholesterol (LDL-C) from discharge to the first control visit. Thirty-five percent of patients achieved a target LDL-C
- Published
- 2023
- Full Text
- View/download PDF